1887

Journal of General Virology header logo

Volume 93, Issue 7

MBT/Pas mouse: a relevant model for the evaluation of Rift Valley fever vaccines Free

Abstract

Currently, there are no worldwide licensed vaccines for Rift Valley fever (RVF) that are both safe and effective. Development and evaluation of vaccines, diagnostics and treatments depend on the availability of appropriate animal models. Animal models are also necessary to understand the basic pathobiology of infection. Here, we report the use of an inbred MBT/Pas mouse model that consistently reproduces RVF disease and serves our purpose for testing the efficacy of vaccine candidates; an attenuated Rift Valley fever virus (RVFV) and a recombinant RVFV–capripoxvirus. We show that this model is relevant for vaccine testing.

  • Received:
  • Accepted:
  • Published Online:
© 2012 SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.042754-0
2012-07-01
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/7/1456.html?itemId=/content/journal/jgv/10.1099/vir.0.042754-0&mimeType=html&fmt=ahah

References

  1. Al-Hazmi M., Ayoola E. A., Abdurahman M., Banzal S., Ashraf J., El-Bushra A., Hazmi A., Abdullah M., Abbo H. other authors 2003; Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis 36:245–252 [View Article][PubMed]
     [Google Scholar]
  2. Anderson G. W. Jr, Slone T. W. Jr, Peters C. J. 1987; Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats. Microb Pathog 2:283–293 [View Article][PubMed]
     [Google Scholar]
  3. Anderson G. W. Jr, Slone T. W. Jr, Peters C. J. 1988; The gerbil, Meriones unguiculatus, a model for Rift Valley fever viral encephalitis. Arch Virol 102:187–196 [View Article][PubMed]
     [Google Scholar]
  4. Anderson G. W. Jr, Slayter M. V., Hall W., Peters C. J. 1990; Pathogenesis of a phleboviral infection (Punta Toro virus) in golden Syrian hamsters. Arch Virol 114:203–212 [View Article][PubMed]
     [Google Scholar]
  5. Anderson G. W. Jr, Rosebrock J. A., Johnson A. J., Jennings G. B., Peters C. J. 1991; Infection of inbred rat strains with Rift Valley fever virus: development of a congenic resistant strain and observations on age-dependence of resistance. Am J Trop Med Hyg 44:475–480[PubMed]
     [Google Scholar]
  6. Berhé G., Minet C., Le Goff C., Barrett T., Ngangnou A., Grillet C., Libeau G., Fleming M., Black D. N., Diallo A. 2003; Development of a dual recombinant vaccine to protect small ruminants against peste-des-petits-ruminants virus and capripoxvirus infections. J Virol 77:1571–1577 [View Article][PubMed]
     [Google Scholar]
  7. Bonhomme F., Guénet J. L. 1996; The laboratory mouse and its wild relatives. In Genetic Variants and Strains of the Laboratory Mouse vol. 2 pp. 1577–1596 Edited by Lyon M. F., Rastan S., Brown S. D. M. Oxford, UK: Oxford University Press;
     [Google Scholar]
  8. Boshra H., Lorenzo G., Rodriguez F., Brun A. 2011; A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge. Vaccine 29:4469–4475 [View Article][PubMed]
     [Google Scholar]
  9. Boyle D. B., Coupar B. E. 1988; A dominant selectable marker for the construction of recombinant poxviruses. Gene 65:123–128 [View Article][PubMed]
     [Google Scholar]
  10. Boyle D. B., Coupar B. E., Both G. W. 1985; Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses. Gene 35:169–177 [View Article][PubMed]
     [Google Scholar]
  11. Calvo-Pinilla E., Rodríguez-Calvo T., Sevilla N., Ortego J. 2009; Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine 28:437–445 [View Article][PubMed]
     [Google Scholar]
  12. Caplen H., Peters C. J., Bishop D. H. 1985; Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66:2271–2277 [View Article][PubMed]
     [Google Scholar]
  13. Cleaveland S., Laurenson M. K., Taylor L. H. 2001; Diseases of humans and their domestic mammals: pathogen characteristics, host range and the risk of emergence. Philos Trans R Soc Lond B Biol Sci 356:991–999 [View Article][PubMed]
     [Google Scholar]
  14. Coetzer J. A. 1977; The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J Vet Res 44:205–211[PubMed]
     [Google Scholar]
  15. Coetzer J. A. 1982; The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves and aborted foetuses. Onderstepoort J Vet Res 49:11–17[PubMed]
     [Google Scholar]
  16. Collett M. S., Purchio A. F., Keegan K., Frazier S., Hays W., Anderson D. K., Parker M. D., Schmaljohn C., Schmidt J., Dalrymple J. M. 1985; Complete nucleotide sequence of the M RNA segment of Rift Valley fever virus. Virology 144:228–245 [View Article][PubMed]
     [Google Scholar]
  17. Collett M. S., Keegan K., Hu S., Sridhar P., Purchio A. F., Ennis W. H., Dalrymple J. M. 1987; Protective subunit immunogens to Rift Valley fever virus from bacteria and recombinant vaccinia virus. In The Biology of Negative Strand Viruses pp. 321–329 Edited by Mahy B., Kolakofsky D. New York, NY: Elsevier; [View Article]
     [Google Scholar]
  18. Davies F. G. 1976; Characteristics of a virus causing a pox disease in sheep and goats in Kenya, with observation on the epidemiology and control. J Hyg (Lond) 76:163–171 [View Article][PubMed]
     [Google Scholar]
  19. Davies F. G. 1981; Sheep and goat pox. In Virus Diseases of Food Animals vol. 2 pp. 733–749 Edited by Gibbs E. P. J. New York, NY: Academic Press;
     [Google Scholar]
  20. de Boer S. M., Kortekaas J., Antonis A. F., Kant J., van Oploo J. L., Rottier P. J., Moormann R. J. M., Bosch B. J. 2010; Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 28:2330–2339 [View Article][PubMed]
     [Google Scholar]
  21. Diallo A., Minet C., Berhe G., Le Goff C., Black D. N., Fleming M., Barrett T., Grillet C., Libeau G. 2002; Goat immune response to capripox vaccine expressing the hemagglutinin protein of peste des petits ruminants. Ann N Y Acad Sci 969:88–91 [View Article][PubMed]
     [Google Scholar]
  22. Digoutte J. P., Peters C. J. 1989; General aspects of the 1987 Rift Valley fever epidemic in Mauritania. Res Virol 140:27–30 [View Article][PubMed]
     [Google Scholar]
  23. do Valle T. Z., Billecocq A., Guillemot L., Alberts R., Gommet C., Geffers R., Calabrese K., Schughart K., Bouloy M. other authors 2010; A new mouse model reveals a critical role for host innate immunity in resistance to Rift Valley fever. J Immunol 185:6146–6156 [View Article][PubMed]
     [Google Scholar]
  24. Dubbs D. R., Kit S. 1964; Isolation and properties of vaccinia mutants deficient in thymidine kinase-inducing activity. Virology 22:214–225 [View Article][PubMed]
     [Google Scholar]
  25. Dungu B., Louw I., Lubisi A., Hunter P., von Teichman B. F., Bouloy M. 2010; Evaluation of the efficacy and safety of the Rift Valley Fever clone 13 vaccine in sheep. Vaccine 28:4581–4587 [View Article][PubMed]
     [Google Scholar]
  26. Easterday B. C. 1965; Rift Valley fever. Adv Vet Sci 10:65–127[PubMed]
     [Google Scholar]
  27. El-Akkad A. M. 1978; Rift Valley fever outbreak in Egypt. October–December 1977. J Egypt Public Health Assoc 53:123–128[PubMed]
     [Google Scholar]
  28. Elliott R. M., Bouloy M., Calisher C. H., Goldbach R., Moyer J. T., Nichol S. T., Pettersson R. F., Plyusnin A., Schmaljohn C. S. 2000; Family Bunyaviridae . In Virus taxonomy. VIIth report of the International Committee on Taxonomy of Viruses pp. 599–621 Edited by van Regenmortel M. H. V., Fauquet C. M., Bishop D. H. L., Carsten E. B., Estes M. K., Lemon S. M., Maniloff J., Mayo M. A., McGeoch D. J., Pringle C. R., Wickner R. B. San Diego, CA: Academic Press;
     [Google Scholar]
  29. Falkner F. G., Moss B. 1988; Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 62:1849–1854[PubMed]
     [Google Scholar]
  30. Fernandez J. C., Billecocq A., Durand J. P., Cêtre-Sossah C., Cardinale E., Marianneau P., Pépin M., Tordo N., Bouloy M. 2012; The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus. Clin Vaccine Immunol 19:5–10 [View Article][PubMed]
     [Google Scholar]
  31. Findlay G. M. 1932; Rift Valley fever or enzootic hepatitis. Trans R Soc Trop Med Hyg 25:229–265 [View Article]
     [Google Scholar]
  32. Findlay G. M., Daubney R. J. 1931; The virus of Rift Valley fever or enzoötic hepatitis. Lancet 218:1350–1351 [View Article]
     [Google Scholar]
  33. Fisher A. F., Tesh R. B., Tonry J., Guzman H., Liu D., Xiao S. Y. 2003; Induction of severe disease in hamsters by two sandfly fever group viruses, Punta Toro and Gabek Forest (Phlebovirus, Bunyaviridae), similar to that caused by Rift Valley fever virus. Am J Trop Med Hyg 69:269–276[PubMed]
     [Google Scholar]
  34. Fontenille D., Traore-Lamizana M., Diallo M., Thonnon J., Digoutte J. P., Zeller H. G. 1998; New vectors of Rift Valley fever in West Africa. Emerg Infect Dis 4:289–293 [View Article][PubMed]
     [Google Scholar]
  35. Gerdes G. H. 2004; Rift Valley fever. Rev Sci Tech 23:613–623[PubMed]
     [Google Scholar]
  36. Heise M. T., Whitmore A., Thompson J., Parsons M., Grobbelaar A. A., Kemp A., Paweska J. T., Madric K., White L. J. other authors 2009; An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus. Epidemiol Infect 137:1309–1318 [View Article][PubMed]
     [Google Scholar]
  37. Holman D. H., Penn-Nicholson A., Wang D., Woraratanadharm J., Harr M. K., Luo M., Maher E. M., Holbrook M. R., Dong J. Y. 2009; A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity. Clin Vaccine Immunol 16:1624–1632 [View Article][PubMed]
     [Google Scholar]
  38. Ikegami T., Makino S. 2009; Rift Valley fever vaccines. Vaccine 27:Suppl. 4D69–D72 [View Article][PubMed]
     [Google Scholar]
  39. Jansen Van Vuren P., Tiemessen C. T., Paweska J. T. 2010; Evaluation of a recombinant Rift Valley fever virus subunit nucleocapsid protein as an immunogen in mice and sheep. The Open Vaccine Journal. 3:114–126 [View Article]
     [Google Scholar]
  40. Jansen van Vuren P., Tiemessen C. T., Paweska J. T. 2011; Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice. PLoS ONE 6:e25027 [View Article][PubMed]
     [Google Scholar]
  41. Johnson K. N., Zeddam J. L., Ball L. A. 2000; Characterization and construction of functional cDNA clones of Pariacoto virus, the first Alphanodavirus isolated outside Australasia. J Virol 74:5123–5132 [View Article][PubMed]
     [Google Scholar]
  42. Kakach L. T., Wasmoen T. L., Collett M. S. 1988; Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression. J Virol 62:826–833[PubMed]
     [Google Scholar]
  43. Keegan K., Collett M. S. 1986; Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. J Virol 58:263–270[PubMed]
     [Google Scholar]
  44. Kitching R. P., Hammond J. M., Taylor W. P. 1987; A single vaccine for the control of capripox infection in sheep and goats. Res Vet Sci 42:53–60[PubMed]
     [Google Scholar]
  45. Kitching R. P., Bhat P. P., Black D. N. 1989; The characterization of African strains of capripoxvirus. Epidemiol Infect 102:335–343 [View Article][PubMed]
     [Google Scholar]
  46. Kortekaas J., Dekker A., de Boer S. M., Weerdmeester K., Vloet R. P., de Wit A. A., Peeters B. P., Moormann R. J. 2010a; Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 28:2271–2276 [View Article][PubMed]
     [Google Scholar]
  47. Kortekaas J., de Boer S. M., Kant J., Vloet R. P., Antonis A. F., Moormann R. J. 2010b; Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 28:4394–4401 [View Article][PubMed]
     [Google Scholar]
  48. Lorenzo G., Martín-Folgar R., Hevia E., Boshra H., Brun A. 2010; Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens. Vaccine 28:2937–2944 [View Article][PubMed]
     [Google Scholar]
  49. Lovejoy T. 2008; Climate change and biodiversity. Rev Sci Tech 27:331–338[PubMed]
     [Google Scholar]
  50. Mandell R. B., Flick R. 2010; Rift Valley fever virus: an unrecognized emerging threat?. Hum Vaccin 6:597–601 [View Article][PubMed]
     [Google Scholar]
  51. Mandell R. B., Koukuntla R., Mogler L. J., Carzoli A. K., Freiberg A. N., Holbrook M. R., Martin B. K., Staplin W. R., Vahanian N. N. other authors 2010; A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397:187–198 [View Article][PubMed]
     [Google Scholar]
  52. McIntosh B. M., Russell D., dos Santos I., Gear J. H. 1980; Rift Valley fever in humans in South Africa. S Afr Med J 58:803–806[PubMed]
     [Google Scholar]
  53. Meegan J. M., Hoogstraal H., Moussa M. I. 1979; An epizootic of Rift Valley fever in Egypt in 1977. Vet Rec 105:124–125 [View Article][PubMed]
     [Google Scholar]
  54. Mims C. A. 1956; Rift Valley Fever virus in mice. I. General features of the infection. Br J Exp Pathol 37:99–109[PubMed]
     [Google Scholar]
  55. Morand S., Guégan J. F. 2008; How the biodiversity sciences may aid biological tools and ecological engineering to assess the impact of climatic changes. Rev Sci Tech 27:355–366[PubMed]
     [Google Scholar]
  56. Morrill J. C., Mebus C. A., Peters C. J. 1997; Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 58:1104–1109[PubMed]
     [Google Scholar]
  57. Näslund J., Lagerqvist N., Habjan M., Lundkvist A., Evander M., Ahlm C., Weber F., Bucht G. 2009; Vaccination with virus-like particles protects mice from lethal infection of Rift Valley fever virus. Virology 385:409–415 [View Article][PubMed]
     [Google Scholar]
  58. Ngichabe C. K., Wamwayi H. M., Barrett T., Ndungu E. K., Black D. N., Bostock C. J. 1997; Trial of a capripoxvirus-rinderpest recombinant vaccine in African cattle. Epidemiol Infect 118:63–70 [View Article][PubMed]
     [Google Scholar]
  59. Ngichabe C. K., Wamwayi H. M., Ndungu E. K., Mirangi P. K., Bostock C. J., Black D. N., Barrett T. 2002; Long term immunity in African cattle vaccinated with a recombinant capripox-rinderpest virus vaccine. Epidemiol Infect 128:343–349 [View Article][PubMed]
     [Google Scholar]
  60. Papin J. F., Verardi P. H., Jones L. A., Monge-Navarro F., Brault A. C., Holbrook M. R., Worthy M. N., Freiberg A. N., Yilma T. D. 2011; Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci U S A 108:14926–14931 [View Article][PubMed]
     [Google Scholar]
  61. Pastoret P. P. 2009; Emerging diseases, zoonoses and vaccines to control them. Vaccine 27:6435–6438 [View Article][PubMed]
     [Google Scholar]
  62. Perrin A., Albina E., Bréard E., Sailleau C., Promé S., Grillet C., Kwiatek O., Russo P., Thiéry R. other authors 2007; Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 25:6774–6783 [View Article][PubMed]
     [Google Scholar]
  63. Peters C. J., Anderson J. 1981; Pathogenesis of Rift Valley fever. Contrib Epidemiol Biostat 3:21–41
     [Google Scholar]
  64. Peters C. J., Linthicum K. J. 1994; Rift Valley Fever. In Handbook of Zoonoses, Section B. Viral, 2nd edn. pp. 125–138 Edited by Beran G. W., Steele J. H. Boca Raton, FL: CRC Press;
     [Google Scholar]
  65. Reed L. J., Muench H. 1938; A simple method of estimating 50 % end points. Am J Hyg 27:493–497
     [Google Scholar]
  66. Ritter M., Bouloy M., Vialat P., Janzen C., Haller O., Frese M. 2000; Resistance to Rift Valley fever virus in Rattus norvegicus: genetic variability within certain ‘inbred’ strains. J Gen Virol 81:2683–2688[PubMed]
     [Google Scholar]
  67. Romero C. H., Barrett T., Evans S. A., Kitching R. P., Gershon P. D., Bostock C., Black D. N. 1993; Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease. Vaccine 11:737–742 [View Article][PubMed]
     [Google Scholar]
  68. Romero C. H., Barrett T., Kitching R. P., Carn V. M., Black D. N. 1994; Protection of cattle against rinderpest and lumpy skin disease with a recombinant capripoxvirus expressing the fusion protein gene of rinderpest virus. Vet Rec 135:152–154 [View Article][PubMed]
     [Google Scholar]
  69. Ross T. M., Bhardwaj N., Bissel S. J., Hartman A. L., Smith D. R. 2012; Animal models of Rift Valley fever virus infection. Virus Res 163:417–423 [View Article][PubMed]
     [Google Scholar]
  70. Saluzzo J. F., Smith J. F. 1990; Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine 8:369–375 [View Article][PubMed]
     [Google Scholar]
  71. Schmaljohn C. S., Parker M. D., Ennis W. H., Dalrymple J. M., Collett M. S., Slizich J. A., Schmaljohn A. L. 1989; Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 170:184–192 [View Article][PubMed]
     [Google Scholar]
  72. Shoemaker T., Boulianne C., Vincent M. J., Pezzanite L., Al-Qahtani M. M., Al-Mazrou Y., Khan A. S., Rollin P. E., Swanepoel R. other authors 2002; Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg Infect Dis 8:1415–1420[PubMed] [CrossRef]
     [Google Scholar]
  73. Slingenbergh J. I., Gilbert M., de Balogh K. I., Wint W. 2004; Ecological sources of zoonotic diseases. Rev Sci Tech 23:467–484[PubMed]
     [Google Scholar]
  74. Smith D. R., Bird B. H., Lewis B., Johnston S. C., McCarthy S., Keeney A., Botto M., Donnelly G., Shamblin J. other authors 2012; Development of a novel nonhuman primate model for Rift Valley fever. J Virol 86:2109–2120 [View Article][PubMed]
     [Google Scholar]
  75. Smithburn K. C. 1949; Rift Valley fever: the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 30:1–16[PubMed]
     [Google Scholar]
  76. Soi R. K., Rurangirwa F. R., McGuire T. C., Rwambo P. M., DeMartini J. C., Crawford T. B. 2010; Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine. Clin Vaccine Immunol 17:1842–1849 [View Article][PubMed]
     [Google Scholar]
  77. Vialat P., Muller R., Vu T. H., Prehaud C., Bouloy M. 1997; Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res 52:43–50 [View Article][PubMed]
     [Google Scholar]
  78. Vialat P., Billecocq A., Kohl A., Bouloy M. 2000; The S segment of Rift Valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice. J Virol 74:1538–1543 [View Article][PubMed]
     [Google Scholar]
  79. von Teichman B., Engelbrecht A., Zulu G., Dungu B., Pardini A., Bouloy M. 2011; Safety and efficacy of Rift Valley fever Smithburn and clone 13 vaccines in calves. Vaccine 29:5771–5777 [View Article][PubMed]
     [Google Scholar]
  80. Wallace D. B., Viljoen G. J. 2005; Immune responses to recombinants of the South African vaccine strain of lumpy skin disease virus generated by using thymidine kinase gene insertion. Vaccine 23:3061–3067 [View Article][PubMed]
     [Google Scholar]
  81. Wallace D. B., Ellis C. E., Espach A., Smith S. J., Greyling R. R., Viljoen G. J. 2006; Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24:7181–7189 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.042754-0
Loading
MBT/Pas mouse: a relevant model for the evaluation of Rift Valley fever vaccines
J. Gen. Virol. 93, 1456 (2012); https://doi.org/10.1099/vir.0.042754-0
/content/journal/jgv/10.1099/vir.0.042754-0
/content/journal/jgv/10.1099/vir.0.042754-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error